

SARS-CoV-2 501Y.V2 escapes neutralization by South A

Nature Medicine

27, 622-625

DOI: 10.1038/s41591-021-01285-x

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?. International Journal of Biological Sciences, 2021, 17, 1476-1485.	6.4	23
2	Key residues of the receptor binding domain in the spike protein of SARS-CoV-2 mediating the interactions with ACE2: a molecular dynamics study. Nanoscale, 2021, 13, 9364-9370.	5.6	22
3	Bioinformatic and MD Analysis of N501Y SARS-CoV-2 (UK) Variant. IFIP Advances in Information and Communication Technology, 2021, , 1-13.	0.7	1
5	OUP accepted manuscript. American Journal of Clinical Pathology, 2021, , .	0.7	7
6	Quantitative epitope analysis reveals drastic 63% reduced immuno-affinity and 60% enhanced transmissibility for SARS-CoV-2 variants. Nanoscale Advances, 2021, 3, 6903-6911.	4.6	2
7	More Than Just Gene Therapy Vectors: Lentiviral Vector Pseudotypes for Serological Investigation. Viruses, 2021, 13, 217.	3.3	13
8	Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants. RSC Advances, 2021, 11, 31460-31476.	3.6	1
9	50 Years of structural immunology. Journal of Biological Chemistry, 2021, 296, 100745.	3.4	15
11	Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. Emerging Microbes and Infections, 2021, 10, 1284-1292.	6.5	25
12	Molecular insights into the binding variance of the SARS-CoV-2 spike with human, cat and dog ACE2 proteins. Physical Chemistry Chemical Physics, 2021, 23, 13752-13759.	2.8	5
13	Rapidly emerging SARS-CoV-2 B.1.1.7 sub-lineage in the United States of America with spike protein D178H and membrane protein V70L mutations. Emerging Microbes and Infections, 2021, 10, 1293-1299.	6.5	18
14	A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations. Emerging Microbes and Infections, 2021, 10, 994-997.	6.5	15
15	COVID-19 vaccines: implementation, limitations and opportunities. Global Health & Medicine, 2021, 3, 1-5.	1.4	28
17	Molecular Epidemiology Surveillance of SARS-CoV-2: Mutations and Genetic Diversity One Year after Emerging. Pathogens, 2021, 10, 184.	2.8	29
18	SARS-CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges. Infectious Disease Reports, 2021, 13, 102-125.	3.1	24
20	The challenge of emerging SARS-CoV-2 mutants to vaccine development. Journal of Genetics and Genomics, 2021, 48, 102-106.	3.9	19
21	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, 592, 616-622.	27.8	1,232
29	Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Science Immunology, 2021, 6, .	11.9	153

#	ARTICLE	IF	CITATIONS
31	Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. Cellular and Molecular Immunology, 2021, 18, 1061-1063.	10.5	94
35	COVID-19: emergence and mutational diversification of SARS-CoV-2. Microbial Biotechnology, 2021, 14, 756-768.	4.2	17
39	Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature, 2021, 593, 142-146.	27.8	574
41	Human Vaccines & Immunotherapeutics: news. Human Vaccines and Immunotherapeutics, 2021, 17, 618-619.	3.3	0
43	Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2. Biology, 2021, 10, 208.	2.8	16
45	Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications. Viruses, 2021, 13, 439.	3.3	107
48	Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host and Microbe, 2021, 29, 463-476.e6.	11.0	1,054
49	Detection of a SARS-CoV-2 variant of concern in South Africa. Nature, 2021, 592, 438-443.	27.8	1,381
51	Immunity to SARS-CoV-2: Lessons Learned. Frontiers in Immunology, 2021, 12, 654165.	4.8	33
52	SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities. JAMA - Journal of the American Medical Association, 2021, 325, 1037.	7.4	288
53	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science, 2021, 372, 1413-1418.	12.6	468
56	SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations. Viruses, 2021, 13, 392.	3.3	92
57	CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants. Open Forum Infectious Diseases, 2021, 8, ofab143.	0.9	83
60	Genomic Characterization of a Novel SARS-CoV-2 Lineage from Rio de Janeiro, Brazil. Journal of Virology, 2021, 95, .	3.4	302
61	Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines, 2021, 9, 243.	4.4	217
62	The envelope protein of SARS-CoV-2 increases intra-Golgi pH and forms a cation channel that is regulated by pH. Journal of Physiology, 2021, 599, 2851-2868.	2.9	51
63	Profiles of current COVID-19 vaccines. Wiener Klinische Wochenschrift, 2021, 133, 271-283.	1.9	32
64	Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nature Medicine, 2021, 27, 917-924.	30.7	617

#	ARTICLE	IF	CITATIONS
65	The effect of spike mutations on SARS-CoV-2 neutralization. Cell Reports, 2021, 34, 108890.	6.4	200
68	Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ, The, 2021, 372, n579.	6.0	648
69	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature, 2021, 593, 130-135.	27.8	1,904
70	Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. Lancet, The, 2021, 397, 1263-1264.	13.7	49
74	COVID vaccine efficacy against the B.1.351 (‘‘South African’’) variant’’The urgent need to lay the groundwork for possible future challenge studies. Human Vaccines and Immunotherapeutics, 2021, , 1-2.	3.3	5
77	Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein. PLoS ONE, 2021, 16, e0250780.	2.5	66
78	SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. ELife, 2021, 10, .	6.0	160
79	SARS-CoV-2 within-host diversity and transmission. Science, 2021, 372, .	12.6	278
82	Dynamic Management of Lung Cancer Care During Surging COVID-19. Frontiers in Surgery, 2021, 8, 663364.	1.4	7
83	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nature Reviews Immunology, 2021, 21, 395-404.	22.7	223
84	Emergence and Spread of SARS-CoV-2 Lineages B.1.1.7 and P.1 in Italy. Viruses, 2021, 13, 794.	3.3	32
85	Neutralizing Antibody Therapeutics for COVID-19. Viruses, 2021, 13, 628.	3.3	99
86	Co-dominant neutralizing epitopes make anti-measles immunity resistant to viral evolution. Cell Reports Medicine, 2021, 2, 100257.	6.5	8
87	Age, Disease Severity and Ethnicity Influence Humoral Responses in a Multi-Ethnic COVID-19 Cohort. Viruses, 2021, 13, 786.	3.3	20
89	SARS-CoV-2 evolution and vaccines: cause for concern?. Lancet Respiratory Medicine,the, 2021, 9, 333-335.	10.7	161
90	Deep Mutational Scanning of Viral Glycoproteins and Their Host Receptors. Frontiers in Molecular Biosciences, 2021, 8, 636660.	3.5	12
92	Versatile and flexible microfluidic qPCR test for high-throughput SARS-CoV-2 and cellular response detection in nasopharyngeal swab samples. PLoS ONE, 2021, 16, e0243333.	2.5	14
93	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. JCI Insight, 2021, 6, .	5.0	52

#	ARTICLE	IF	CITATIONS
94	COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. <i>Frontiers in Immunology</i> , 2021, 12, 669339.	4.8	81
96	SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses. <i>Cell Reports Medicine</i> , 2021, 2, 100252.	6.5	33
97	Resurgence of SARS-CoV-2: Detection by community viral surveillance. <i>Science</i> , 2021, 372, 990-995.	12.6	91
98	The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. <i>Lancet, The</i> , 2021, 397, 1265-1275.	13.7	282
99	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021, 184, 2332-2347.e16.	28.9	784
100	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. <i>Cell Host and Microbe</i> , 2021, 29, 529-539.e3.	11.0	324
102	Dissemination and evolution of SARS-CoV-2 in the early pandemic phase in South America. <i>Journal of Medical Virology</i> , 2021, 93, 4496-4507.	5.0	5
103	A human coronavirus evolves antigenically to escape antibody immunity. <i>PLoS Pathogens</i> , 2021, 17, e1009453.	4.7	183
104	Insights into SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2820-2826.	6.4	49
107	Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. <i>Cell</i> , 2021, 184, 2372-2383.e9.	28.9	1,166
109	Structural impact on SARS-CoV-2 spike protein by D614G substitution. <i>Science</i> , 2021, 372, 525-530.	12.6	344
110	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	13.7	540
112	Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines. <i>ACS Central Science</i> , 2021, 7, 757-767.	11.3	46
113	Temporal Dominance of B.1.1.7 over B.1.354 SARS-CoV-2 Variant: A Hypothesis Based on Areas of Variant Co-Circulation. <i>Life</i> , 2021, 11, 375.	2.4	9
114	SARS-CoV-2 one year on: evidence for ongoing viral adaptation. <i>Journal of General Virology</i> , 2021, 102, .	2.9	137
116	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. <i>Biochemistry</i> , 2021, 60, 1459-1484.	2.5	62
118	Intermolecular Interaction Analyses on SARS-CoV-2 Spike Protein Receptor Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor-Blocking Antibody/Peptide Using Fragment Molecular Orbital Calculation. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 4059-4066.	4.6	22
119	Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. <i>Cell Host and Microbe</i> , 2021, 29, 516-521.e3.	11.0	199

#	ARTICLE	IF	CITATIONS
120	Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. <i>Science</i> , 2021, 372, 815-821.	12.6	1,125
123	<scp>ACE2–based</scp> decoy receptors for <scp>SARS</scp> coronavirus 2. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 1065-1078.	2.6	23
127	Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America. <i>Viruses</i> , 2021, 13, 930.	3.3	13
129	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , 2021, 594, 553-559.	27.8	199
130	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 818-823.	12.6	309
131	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1899-1909.	27.0	541
134	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. <i>Cell Host and Microbe</i> , 2021, 29, 806-818.e6.	11.0	49
135	Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 595-605.	4.0	20
140	Multifactorial Traits of SARS-CoV-2 Cell Entry Related to Diverse Host Proteases and Proteins. <i>Biomolecules and Therapeutics</i> , 2021, 29, 249-262.	2.4	2
142	SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T–cell recognition. <i>Cell Reports Medicine</i> , 2021, 2, 100286.	6.5	18
146	Identification of evolutionarily stable functional and immunogenic sites across the SARS-CoV-2 proteome and greater coronavirus family. <i>Bioinformatics</i> , 2021, 37, 4033-4040.	4.1	6
147	New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection. <i>Pharmaceuticals</i> , 2021, 14, 503.	3.8	6
148	Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro. <i>Viruses</i> , 2021, 13, 935.	3.3	22
149	New SARS-CoV-2 Variants “ Clinical, Public Health, and Vaccine Implications. <i>New England Journal of Medicine</i> , 2021, 384, 1866-1868.	27.0	581
150	Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2021, 40, 665-706.	1.1	12
151	Practical guidance for clinical laboratories for SARS-CoV-2 serology testing. <i>Canada Communicable Disease Report</i> , 2021, 47, 171-183.	1.3	12
152	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 314-338.	13.7	75
153	Prioritisation of Compounds for 3CLpro Inhibitor Development on SARS-CoV-2 Variants. <i>Molecules</i> , 2021, 26, 3003.	3.8	23

#	ARTICLE	IF	CITATIONS
154	Severe acute respiratory syndrome coronavirus 2: Mutations and variants of concern – the Indian scenario. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 6, 66-71.	0.0	4
155	siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses. <i>Molecular Pharmaceutics</i> , 2021, 18, 2105-2121.	4.6	34
156	Computational <i>Ab Initio</i> Interaction Analyses between Neutralizing Antibody and SARS-CoV-2 Variant Spike Proteins Using the Fragment Molecular Orbital Method. <i>Bulletin of the Chemical Society of Japan</i> , 2021, 94, 1794-1798.	3.2	4
157	Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein–Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2021, 7, 1519-1534.	3.8	77
158	Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. <i>Cell Research</i> , 2021, 31, 732-741.	12.0	124
160	SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. <i>Nature Medicine</i> , 2021, 27, 759-761.	30.7	65
161	SARS-CoV-2 worldwide replication drives rapid rise and selection of mutations across the viral genome: a time-course study – potential challenge for vaccines and therapies. <i>EMBO Molecular Medicine</i> , 2021, 13, e14062.	6.9	28
163	SARS-CoV-2: One Year in the Pandemic. What Have We Learned, the New Vaccine Era and the Threat of SARS-CoV-2 Variants. <i>Biomedicines</i> , 2021, 9, 611.	3.2	10
164	Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. <i>Frontiers in Immunology</i> , 2021, 12, 688436.	4.8	26
165	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1885-1898.	27.0	1,077
167	Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 72-82.	5.7	11
168	Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5464.	4.1	9
170	Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian state of Karnataka. <i>Wellcome Open Research</i> , 2021, 6, 110.	1.8	14
171	A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus. <i>MedComm</i> , 2021, 2, 430-441.	7.2	37
172	Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Vaccines</i> , 2021, 9, 467.	4.4	228
173	Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center. <i>Clinical Infectious Diseases</i> , 2022, 74, 821-828.	5.8	47
174	Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. <i>Molecules and Cells</i> , 2021, 44, 392-400.	2.6	22
175	Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. <i>Nature Communications</i> , 2021, 12, 3815.	12.8	44

#	ARTICLE	IF	CITATIONS
176	Protective efficacy of Ad26.COVS.2 against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021, 596, 423-427.	27.8	40
177	Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). <i>New England Journal of Medicine</i> , 2021, 384, 2161-2163.	27.0	111
178	Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19. <i>Journal of Nanobiotechnology</i> , 2021, 19, 173.	9.1	45
179	Up State of the SARS-COV-2 Spike Homotrimer Favors an Increased Virulence for New Variants. <i>Frontiers in Medical Technology</i> , 2021, 3, 694347.	2.5	22
181	Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. <i>Nature Communications</i> , 2021, 12, 3661.	12.8	48
182	Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	198
184	In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms. <i>Frontiers in Microbiology</i> , 2021, 12, 698944.	3.5	40
186	Role of SARS-CoV-2 and ACE2 variations in COVID-19. <i>Biomedical Journal</i> , 2021, 44, 235-244.	3.1	20
187	Longitudinal Antibody Dynamics Against Structural Proteins of SARS-CoV-2 in Three COVID-19 Patients Shows Concurrent Development of IgA, IgM, and IgG. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 2497-2506.	3.5	9
188	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	3.6	4
189	SARS-CoV-2 variants, spike mutations and immune escape. <i>Nature Reviews Microbiology</i> , 2021, 19, 409-424.	28.6	2,650
191	Safety and Efficacy of Single-Dose Ad26.COVS.2 Vaccine against Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2187-2201.	27.0	1,954
192	An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. <i>Scientific Reports</i> , 2021, 11, 12740.	3.3	54
194	Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?. <i>Viruses</i> , 2021, 13, 1192.	3.3	150
195	Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by the B.1.351 variant in the Eastern Cape, South Africa. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100013.	1.0	20
196	Smartphone screen testing, a novel pre-diagnostic method to identify SARS-CoV-2 infectious individuals. <i>ELife</i> , 2021, 10, .	6.0	9
197	Acceptance of COVID-19 Vaccine among the Healthcare Workers in the Eastern Cape, South Africa: A Cross Sectional Study. <i>Vaccines</i> , 2021, 9, 666.	4.4	51
198	Immunogenicity of Ad26.COVS.2 vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , 2021, 596, 268-272.	27.8	290

#	ARTICLE	IF	CITATIONS
200	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , 2021, 54, 1276-1289.e6.	14.3	112
201	An Overview of the Epidemiologic, Diagnostic and Treatment Approaches of COVID-19: What do We Know?. <i>Public Health Reviews</i> , 2021, 42, 1604061.	3.2	6
205	Novel Highly Divergent SARS-CoV-2 Lineage With the Spike Substitutions L249S and E484K. <i>Frontiers in Medicine</i> , 2021, 8, 697605.	2.6	6
206	Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes. <i>Vaccines</i> , 2021, 9, 702.	4.4	5
207	Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. <i>Science</i> , 2021, 373, .	12.6	318
208	Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan. <i>PLoS Pathogens</i> , 2021, 17, e1009619.	4.7	40
209	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 642-648.	12.6	211
210	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108.	27.8	222
212	CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 4048.	12.8	45
213	Inhibitory effect on SARS-CoV-2 infection of neferine by blocking Ca ²⁺ -dependent membrane fusion. <i>Journal of Medical Virology</i> , 2021, 93, 5825-5832.	5.0	20
214	SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. <i>Viruses</i> , 2021, 13, 1211.	3.3	35
215	Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes. <i>MBio</i> , 2021, 12, e0069621.	4.1	61
216	SARS-CoV-2 variants of concern: the knowns and unknowns. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100868.	1.4	5
220	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence and Reinfection. <i>Clinical Infectious Diseases</i> , 2022, 74, 237-245.	5.8	59
221	Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab295.	0.9	22
226	Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveals the Allosteric Duality of Functionally Adaptable Hotspots. <i>Journal of Chemical Theory and Computation</i> , 2021, 17, 4578-4598.	5.3	39
227	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021, 184, 3086-3108.	28.9	309
228	Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 718-723.	27.8	128

#	ARTICLE	IF	CITATIONS
229	Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets. <i>Frontiers in Immunology</i> , 2021, 12, 694857.	4.8	9
230	COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. <i>Molecular Biotechnology</i> , 2021, 63, 885-897.	2.4	8
233	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 3991.	12.8	241
234	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. <i>Cell</i> , 2021, 184, 3205-3221.e24.	28.9	73
235	Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 226.	17.1	103
236	COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern. <i>Frontiers in Genetics</i> , 2021, 12, 693916.	2.3	55
237	FnCas9-based CRISPR diagnostic for rapid and accurate detection of major SARS-CoV-2 variants on a paper strip. <i>ELife</i> , 2021, 10, .	6.0	53
238	Despite vaccination, China needs non-pharmaceutical interventions to prevent widespread outbreaks of COVID-19 in 2021. <i>Nature Human Behaviour</i> , 2021, 5, 1009-1020.	12.0	81
239	Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. <i>Cell</i> , 2021, 184, 3426-3437.e8.	28.9	424
240	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2370.	7.4	307
241	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021, 373, .	12.6	174
243	Human immunoglobulin from transchromosomal bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	3.3	20
244	Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells. <i>Cells</i> , 2021, 10, 1761.	4.1	34
246	Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries. <i>Cell Discovery</i> , 2021, 7, 57.	6.7	28
247	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , 2021, 373, 648-654.	12.6	385
248	Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection. <i>Kidney International Reports</i> , 2021, 6, 1799-1809.	0.8	13
249	Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?. <i>Stem Cell Research and Therapy</i> , 2021, 12, 425.	5.5	15
250	An Update on Severe Acute Respiratory Syndrome Coronavirus 2 Diversity in the US National Capital Region: Evolution of Novel and Variants of Concern. <i>Clinical Infectious Diseases</i> , 2022, 74, 1419-1428.	5.8	24

#	ARTICLE	IF	CITATIONS
251	An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. <i>Cell Reports</i> , 2021, 36, 109452.	6.4	90
252	Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. <i>Journal of Travel Medicine</i> , 2021, 28, .	3.0	94
254	Molecular definition of severe acute respiratory syndrome coronavirus 2 receptorâ€binding domain mutations: Receptor affinity versus neutralization of receptor interaction. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 143-149.	5.7	26
255	Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC:) Tj ETQq1 1 0.784314 rgBT /Overlook	4.4	94
258	Has translational genomics come of age in Africa?. <i>Human Molecular Genetics</i> , 2021, 30, R164-R173.	2.9	11
260	SARS-CoV-2 Mutations and their Viral Variants. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 10-22.	7.2	113
261	Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. <i>ELife</i> , 2021, 10, .	6.0	42
262	The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101606.	0.6	94
263	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021, 12, 4196.	12.8	332
264	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. <i>Cell Host and Microbe</i> , 2021, 29, 1093-1110.	11.0	73
265	Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ TÂcell reactivity in infected or vaccinated individuals. <i>Cell Reports Medicine</i> , 2021, 2, 100355.	6.5	490
266	Contemporary narrative review of treatment options for COVID â19. <i>Respirology</i> , 2021, 26, 745-767.	2.3	12
267	Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. <i>International Journal of Biological Macromolecules</i> , 2021, 183, 203-212.	7.5	28
268	Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. <i>Cell Reports</i> , 2021, 36, 109385.	6.4	23
269	Hypothesis: Possible influence of antivector immunity and SARSâCoVâ2 variants on efficacy of ChAdOx1 nCoVâ19 vaccine. <i>British Journal of Pharmacology</i> , 2022, 179, 218-226.	5.4	11
271	Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses. <i>Molecular Biology</i> , 2021, 55, 538-547.	1.3	2
272	Ongoing global and regional adaptive evolution of SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	196
273	The success of SARS-CoV-2 vaccines and challenges ahead. <i>Cell Host and Microbe</i> , 2021, 29, 1111-1123.	11.0	67

#	ARTICLE	IF	CITATIONS
274	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. <i>Cell Reports</i> , 2021, 36, 109353.	6.4	95
275	A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants. <i>Journal of Clinical Medicine</i> , 2021, 10, 3276.	2.4	18
276	Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 1498.	3.3	33
277	Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. <i>ACS Infectious Diseases</i> , 2021, 7, 2546-2564.	3.8	34
278	Inhalable nanocatchers for SARS-CoV-2 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	34
279	COVID-19 transmission and the safety of air travel during the pandemic: a scoping review. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 415-422.	3.1	13
280	SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. <i>Eurosurveillance</i> , 2021, 26, .	7.0	31
281	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	4.0	136
282	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021, 597, 103-108.	27.8	220
283	SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. <i>Cell</i> , 2021, 184, 3936-3948.e10.	28.9	241
285	hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants. <i>Cell Discovery</i> , 2021, 7, 54.	6.7	10
286	Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 4210.	12.8	82
288	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 4598.	12.8	88
289	Interpreting estimates of coronavirus disease 2019 (COVID-19) vaccine efficacy and effectiveness to inform simulation studies of vaccine impact: a systematic review. <i>Wellcome Open Research</i> , 0, 6, 185.	1.8	17
290	Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2. <i>PLoS ONE</i> , 2021, 16, e0254734.	2.5	12
291	The Pathogenic Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Possible Mechanisms for Immune Evasion?. <i>Frontiers in Immunology</i> , 2021, 12, 693579.	4.8	2
292	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. <i>Cell Host and Microbe</i> , 2021, 29, 1151-1161.e5.	11.0	36
294	Catching SARS-CoV-2 by Sequence Hybridization: a Comparative Analysis. <i>MSystems</i> , 2021, 6, e0039221.	3.8	11

#	ARTICLE	IF	CITATIONS
295	Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor. <i>Cell and Bioscience</i> , 2021, 11, 168.	4.8	69
296	Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. <i>Cell Reports</i> , 2021, 36, 109604.	6.4	67
297	B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies. <i>MBio</i> , 2021, 12, e0138621.	4.1	52
299	An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection. <i>Cell and Bioscience</i> , 2021, 11, 164.	4.8	10
300	The association between mechanical ventilator compatible bed occupancy and mortality risk in intensive care patients with COVID-19: a national retrospective cohort study. <i>BMC Medicine</i> , 2021, 19, 213.	5.5	28
301	Structure-guided TÂcell vaccine design for SARS-CoV-2 variants and sarbecoviruses. <i>Cell</i> , 2021, 184, 4401-4413.e10.	28.9	65
302	Effect of time and titer in convalescent plasma therapy for COVID-19. <i>IScience</i> , 2021, 24, 102898.	4.1	16
303	Minimally instrumented SHERLOCK (miSHERLOCK) for CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging variants. <i>Science Advances</i> , 2021, 7, .	10.3	189
304	Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes. <i>Nature Communications</i> , 2021, 12, 4676.	12.8	74
306	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. <i>Nature Communications</i> , 2021, 12, 4886.	12.8	65
308	Probing the Increased Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 (Indian) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.5	3
309	Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 788-796.	6.1	40
310	Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies. <i>PLoS ONE</i> , 2021, 16, e0253574.	2.5	10
311	Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 693775.	4.8	38
312	The impact of high-resolution structural data on stemming the COVID-19 pandemic. <i>Current Opinion in Virology</i> , 2021, 49, 127-138.	5.4	2
313	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	17.1	68
316	SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom. <i>EClinicalMedicine</i> , 2021, 38, 101021.	7.1	24
317	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021, 54, 1853-1868.e7.	14.3	230

#	ARTICLE	IF	CITATIONS
318	Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. <i>Nature Reviews Immunology</i> , 2021, 21, 626-636.	22.7	777
319	Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 3023-3033.	2.6	35
320	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021, 12, 5061.	12.8	150
321	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. <i>Immunity</i> , 2021, 54, 2385-2398.e10.	14.3	46
322	Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies. <i>EMBO Journal</i> , 2021, 40, e107985.	7.8	69
323	Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection. <i>Cell Discovery</i> , 2021, 7, 71.	6.7	26
324	The rapid adaptation of SARS-CoV-2—rise of the variants: transmission and resistance. <i>Journal of Microbiology</i> , 2021, 59, 807-818.	2.8	18
326	The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. <i>Exploration of Immunology</i> , 2021, , 199-225.	0.3	5
328	Mass spectrometry-based proteomics in basic and translational research of SARS-CoV-2 coronavirus and its emerging mutants. <i>Clinical Proteomics</i> , 2021, 18, 19.	2.1	12
329	Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo. <i>Cell Discovery</i> , 2021, 7, 65.	6.7	51
331	Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. <i>Biochemical and Biophysical Research Communications</i> , 2021, 566, 135-140.	2.1	46
332	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	14.5	57
333	Severe Acute Respiratory Syndrome Coronavirus-2 Inactivation Activity of the Polyphenol-Rich Tea Leaf Extract with Concentrated Theaflavins and Other Virucidal Catechins. <i>Molecules</i> , 2021, 26, 4803.	3.8	6
334	The Emergence and Spread of Novel SARS-CoV-2 Variants. <i>Frontiers in Public Health</i> , 2021, 9, 696664.	2.7	24
335	Potential SARS-CoV-2 vaccines: Concept, progress, and challenges. <i>International Immunopharmacology</i> , 2021, 97, 107622.	3.8	14
336	A novel nano therapeutic using convalescent plasma derived exosomal (CPExo) for COVID-19: A combined hyperactive immune modulation and diagnostics. <i>Chemico-Biological Interactions</i> , 2021, 344, 109497.	4.0	16
337	Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab430.	0.9	18
338	The ongoing evolution of variants of concern and interest of SARS-CoV-2 in Brazil revealed by convergent indels in the amino (N)-terminal domain of the spike protein. <i>Virus Evolution</i> , 2021, 7, veab069.	4.9	31

#	ARTICLE	IF	CITATIONS
339	Myxobacterial depsipeptide chondramides interrupt SARS-CoV-2 entry by targeting its broad, cell tropic spike protein. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 12209-12220.	3.5	10
340	A potentially neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. <i>Immunity</i> , 2021, 54, 2399-2416.e6.	14.3	79
341	Recombinant <i>Mycobacterium paragordoniae</i> Expressing SARS-CoV-2 Receptor-Binding Domain as a Vaccine Candidate Against SARS-CoV-2 Infections. <i>Frontiers in Immunology</i> , 2021, 12, 712274.	4.8	10
342	Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. <i>Nature Communications</i> , 2021, 12, 5215.	12.8	22
343	Lectin from <i>Triticum vulgaris</i> (WGA) Inhibits Infection with SARS-CoV-2 and Its Variants of Concern Alpha and Beta. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10205.	4.1	17
344	Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen. <i>Frontiers in Immunology</i> , 2021, 12, 707977.	4.8	21
345	Immunity elicited by natural infection or Ad26.COVS.2 vaccination protects hamsters against SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj3789.	12.4	32
346	Genomic surveillance to combat COVID-19: challenges and opportunities. <i>Lancet Microbe</i> , The, 2021, 2, e481-e484.	7.3	122
347	A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. <i>European Journal of Immunology</i> , 2022, 52, 770-783.	2.9	24
348	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. <i>Science Translational Medicine</i> , 2021, 13, eabj2641.	12.4	15
350	Tracking down B.1.351 SARS-CoV-2 variant in Pakistan through genomic surveillance. <i>Journal of Medical Virology</i> , 2022, 94, 32-34.	5.0	7
351	S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 343.	17.1	24
352	Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting. <i>Diagnostics</i> , 2021, 11, 1788.	2.6	8
353	Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. <i>The Lancet Global Health</i> , 2021, 9, e1216-e1225.	6.3	131
356	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100405.	6.5	110
357	A Novel Real-Time RT-PCR-Based Methodology for the Preliminary Typing of SARS-CoV-2 Variants, Employing Non-Extendable LNA Oligonucleotides and Three Signature Mutations at the Spike Protein Receptor-Binding Domain. <i>Life</i> , 2021, 11, 1015.	2.4	5
358	Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0052721.	3.9	71
359	Bispecific antibodies targeting distinct regions of the spike protein potentially neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj5413.	12.4	79

#	ARTICLE	IF	CITATIONS
360	Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. <i>Science Translational Medicine</i> , 2021, 13, eabh2624.	12.4	155
361	Genetic drift in the genome of SARS-CoV-2 and its global health concern. <i>Journal of Medical Virology</i> , 2022, 94, 88-98.	5.0	17
362	Could live attenuated vaccines better control COVID-19?. <i>Vaccine</i> , 2021, 39, 5719-5726.	3.8	29
363	A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis. <i>Current Issues in Molecular Biology</i> , 2021, 43, 1212-1225.	2.4	9
364	Genome interaction of the virus and the host genes and non-coding RNAs in SARS-CoV-2 infection. <i>Immunobiology</i> , 2021, 226, 152130.	1.9	10
366	An ultrapotent pan- β -coronavirus lineage B (β -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	11.0	25
369	Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction. <i>Journal of Biological Chemistry</i> , 2021, 297, 101202.	3.4	28
370	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 1372-1377.	12.6	459
371	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. <i>Lancet HIV</i> , 2021, 8, e568-e580.	4.7	124
372	Antibody screening at reduced pH enables preferential selection of potentially neutralizing antibodies targeting SARS-CoV-2. <i>AIChE Journal</i> , 2021, 67, e17440.	3.6	4
373	Mass Spectrometry-based Proteomics and Glycoproteomics in COVID-19 Biomarkers Identification: A Mini-review. <i>Journal of Analysis and Testing</i> , 2021, 5, 298-313.	5.1	17
375	The "Delta Plus" COVID-19 variant has evolved to become the next potential variant of concern: mutation history and measures of prevention. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, 33, 109-112.	1.3	43
376	Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2021, 13, eabj0847.	12.4	40
377	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nature Microbiology</i> , 2021, 6, 1233-1244.	13.3	237
378	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. <i>Science Advances</i> , 2021, 7, eabj5365.	10.3	83
379	The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. <i>Nature Medicine</i> , 2021, 27, 1518-1524.	30.7	178
380	Protocol for safe, affordable, and reproducible isolation and quantitation of SARS-CoV-2 RNA from wastewater. <i>PLoS ONE</i> , 2021, 16, e0257454.	2.5	16
381	Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 752003.	4.8	62

#	ARTICLE	IF	CITATIONS
384	E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104941.	2.3	58
388	Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin) Tj ETQq1 1 0.784314 rgBT / Qverlock 10	3.5	19
390	The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages. <i>Cell</i> , 2021, 184, 5189-5200.e7.	28.9	186
391	Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 301.e1-301.e8.	6.0	28
392	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	16.3	778
393	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	3.2	87
394	Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern. <i>IScience</i> , 2021, 24, 103006.	4.1	23
395	A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels. <i>Scientific Reports</i> , 2021, 11, 18428.	3.3	10
396	Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100164.	5.6	83
397	The Immune Response to SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2021, 13, 1911.	3.3	18
398	Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation. <i>Journal of Virology</i> , 2021, 95, e0096621.	3.4	17
400	Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19. <i>EBioMedicine</i> , 2021, 71, 103519.	6.1	13
401	Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104971.	2.3	19
402	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	28.9	131
403	A look into the future of the COVID-19 pandemic in Europe: an expert consultation. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100185.	5.6	72
404	COVID-19 vaccine candidates and vaccine development platforms available worldwide. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 675-682.	5.3	8
405	Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development. <i>International Reviews of Immunology</i> , 2022, 41, 393-413.	3.3	13
406	Vaccines efficacy to SARS-CoV-2 variants require holistic knowledge of viral immunology and protein biochemistry. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4128-4130.	3.3	1

#	ARTICLE	IF	CITATIONS
407	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. <i>Nature</i> , 2021, 600, 512-516.	27.8	174
408	Impact of the Delta variant on vaccine efficacy and response strategies. <i>Expert Review of Vaccines</i> , 2021, 20, 1201-1209.	4.4	177
409	A one-step real-time RT-PCR assay for simultaneous typing of SARS-CoV-2 mutations associated with the E484K and N501Y spike protein amino-acid substitutions. <i>Journal of Virological Methods</i> , 2021, 296, 114242.	2.1	10
410	Temporal spread and evolution of SARS-CoV-2 in the second pandemic wave in Brazil. <i>Journal of Medical Virology</i> , 2022, 94, 926-936.	5.0	11
411	In silico study of some selective phytochemicals against a hypothetical SARS-CoV-2 spike RBD using molecular docking tools. <i>Computers in Biology and Medicine</i> , 2021, 137, 104818.	7.0	23
412	COVID-19, the first pandemic in the post-genomic era. <i>Current Opinion in Virology</i> , 2021, 50, 40-48.	5.4	40
413	Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives. <i>International Immunopharmacology</i> , 2021, 99, 108036.	3.8	10
414	Investigating the possible origin and transmission routes of SARS-CoV-2 genomes and variants of concern in Bangladesh. <i>Infection, Genetics and Evolution</i> , 2021, 95, 105057.	2.3	2
415	Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. <i>Infection, Genetics and Evolution</i> , 2021, 95, 105038.	2.3	110
416	Phylogenetic reconstruction of the initial stages of the spread of the SARS-CoV-2 virus in the Eurasian and American continents by analyzing genomic data. <i>Virus Research</i> , 2021, 305, 198551.	2.2	9
417	SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 3020-3029.	4.3	78
418	E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 109, 108035.	2.4	52
419	Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System. <i>Nephron</i> , 2021, 145, 392-403.	1.8	58
420	Comparative Analysis of SARS-CoV-2-Specific B Cell and Humoral Responses Elicited by Sputnik V in Naïve and COVID-19-Recovered Vaccine Recipients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
421	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. <i>Oxford Open Immunology</i> , 2021, 2, iqab010.	2.8	18
423	Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy. <i>Emerging Microbes and Infections</i> , 2021, 10, 710-712.	6.5	7
424	Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. <i>Emerging Microbes and Infections</i> , 2021, 10, 1390-1403.	6.5	16
425	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. <i>Emerging Microbes and Infections</i> , 2021, 10, 507-535.	6.5	202

#	ARTICLE	IF	CITATIONS
429	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. <i>Science</i> , 2021, 374, 423-431.	12.6	144
431	Thermodynamics and kinetics in antibody resistance of the 501Y.V2 SARS-CoV-2 variant. <i>RSC Advances</i> , 2021, 11, 33438-33446.	3.6	3
432	SARS-CoV-2 Variants of Concern. <i>Yonsei Medical Journal</i> , 2021, 62, 961.	2.2	183
433	Divergence of Delta and Beta Variants and SARS-CoV-2 Evolved in Advanced HIV Disease into Two Serological Phenotypes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
434	A comprehensive review of the analysis and integration of omics data for SARS-CoV-2 and COVID-19. <i>Briefings in Bioinformatics</i> , 2022, 23, .	6.5	9
435	Comprehensive serological strategy for the diagnosis and monitoring of SARS-CoV-2. From infection to vaccine control. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 44-45.	1.3	0
436	INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2021, 6, 121.	6.0	36
437	HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave. <i>ELife</i> , 2021, 10, .	6.0	28
438	Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission. <i>Science Immunology</i> , 2021, 6, eabm3131.	11.9	37
439	Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. <i>IScience</i> , 2021, 24, 103341.	4.1	47
440	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	6.0	569
441	The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2673-2675.	10.5	25
442	Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2560-2562.	10.5	11
443	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	13.3	94
444	The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization. <i>Molecular Biology Reports</i> , 2022, 49, 647-656.	2.3	11
445	Assessing Multiplex Tiling PCR Sequencing Approaches for Detecting Genomic Variants of SARS-CoV-2 in Municipal Wastewater. <i>MSystems</i> , 2021, 6, e0106821.	3.8	26
446	Mechanisms of SARS-CoV-2 entry into cells. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 3-20.	37.0	1,532
447	The global epidemic of SARS-CoV-2 variants and their mutational immune escape. <i>Journal of Medical Virology</i> , 2022, 94, 847-857.	5.0	80

#	ARTICLE	IF	CITATIONS
448	Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. <i>Journal of Virology</i> , 2022, 96, JVI0111021.	3.4	29
449	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	4.4	90
450	Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy. <i>Advanced Materials</i> , 2021, 33, e2103471.	21.0	60
451	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	12.6	83
452	Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models. <i>Cell Reports Medicine</i> , 2021, 2, 100450.	6.5	17
453	Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 720357.	3.9	7
454	Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation. <i>Vaccines</i> , 2021, 9, 1124.	4.4	3
455	Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. <i>Nature Communications</i> , 2021, 12, 5839.	12.8	67
456	Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme—The South African Experience. <i>Viruses</i> , 2021, 13, 2050.	3.3	5
458	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. <i>Nature Communications</i> , 2021, 12, 6097.	12.8	38
459	Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2-infected individuals reveal unlinked immune signatures. <i>Science Advances</i> , 2021, 7, eabi6533.	10.3	16
462	Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 6103.	12.8	117
463	SARS-CoV-2 UK, South African and Brazilian Variants in Karachi- Pakistan. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 724208.	3.5	1
464	Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. <i>Cell Discovery</i> , 2021, 7, 96.	6.7	21
465	Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner. <i>Cell Host and Microbe</i> , 2021, 29, 1611-1619.e5.	11.0	106
466	Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. <i>Cmaj</i> , 2021, 193, E1619-E1625.	2.0	220
467	Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. <i>Science Advances</i> , 2021, 7, eabj3107.	10.3	23
470	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. <i>Npj Vaccines</i> , 2021, 6, 129.	6.0	47

#	ARTICLE	IF	CITATIONS
471	SARS-CoV-2 beta variant substitutions alter spike glycoprotein receptor binding domain structure and stability. <i>Journal of Biological Chemistry</i> , 2021, 297, 101371.	3.4	6
473	Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19. <i>ACS Central Science</i> , 2021, 7, 1980-1985.	11.3	91
474	High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 2177.	3.3	21
475	RT-qPCR assays for SARS-CoV-2 variants of concern in wastewater reveals compromised vaccination-induced immunity. <i>Water Research</i> , 2021, 207, 117808.	11.3	39
476	SARS-CoV-2 surveillance in Italy through phylogenomic inferences based on Hamming distances derived from pan-SNPs, -MNP and -InDels. <i>BMC Genomics</i> , 2021, 22, 782.	2.8	12
477	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. <i>Medicinski Podmladak</i> , 2021, 72, 20-29.	0.0	3
478	Getting out of crises: Environmental, social-ecological and evolutionary research is needed to avoid future risks of pandemics. <i>Environment International</i> , 2022, 158, 106915.	10.0	18
479	SARS-CoV-2 Mutations and Variants: what do we know so far?. <i>Microbes, Infection and Chemotherapy</i> , 0, 1, e1256.	0.0	5
480	A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.8	4
481	Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. <i>ACS Central Science</i> , 2021, 7, 1863-1873.	11.3	20
482	Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant. <i>Scientific Reports</i> , 2021, 11, 21849.	3.3	26
483	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. <i>Scientific Reports</i> , 2021, 11, 21601.	3.3	20
484	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. <i>Epidemiology and Infection</i> , 2021, 149, 1-24.	2.1	43
485	Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model. <i>EBioMedicine</i> , 2021, 73, 103675.	6.1	26
487	Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: Pathologic, physiologic, and detailed molecular profiling. <i>Translational Research</i> , 2022, 240, 1-16.	5.0	33
488	Assessment of the COVID-19 epidemiological situation in St. Petersburg. <i>Zhurnal Mikrobiologii Epidemiologii i Immunobiologii</i> , 2021, 98, 497-511.	1.0	14
489	Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. <i>Nature Communications</i> , 2021, 12, 6304.	12.8	42
490	Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 31-56.	1.4	8

#	ARTICLE	IF	CITATIONS
491	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	4.8	44
492	Genomic surveillance reveals the detection of SARS-CoV-2 delta, beta, and gamma VOCs during the third wave in Pakistan. <i>Journal of Medical Virology</i> , 2022, 94, 1115-1129.	5.0	21
494	Coronavirus Disease Update on Epidemiology, Virology, and Prevention. <i>Compendium of Continuing Education in Dentistry</i> (Jamesburg, NJ: 1995), 2021, 42, 280-289.	0.1	0
495	Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. <i>Theranostics</i> , 2022, 12, 1-17.	10.0	6
496	Update of the epidemiological distribution of COVID-19 variants: a review article. <i>Revista Da Associação Médica Brasileira</i> , 2021, 67, 1368-1371.	0.7	1
497	D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 9035-9045.	3.6	34
498	A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. <i>Npj Vaccines</i> , 2021, 6, 143.	6.0	47
499	Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in <i>Nicotiana benthamiana</i> Plant as a Vaccine Candidate against COVID-19. <i>Vaccines</i> , 2021, 9, 1337.	4.4	28
500	Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 753444.	3.9	13
501	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. <i>Nature</i> , 2022, 601, 410-414.	27.8	71
502	Identification of a therapeutic interfering particle—A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance. <i>Cell</i> , 2021, 184, 6022-6036.e18.	28.9	36
503	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. <i>Archives of Virology</i> , 2022, 167, 293-305.	2.1	28
504	N501Y and K417N Mutations in the Spike Protein of SARS-CoV-2 Alter the Interactions with Both hACE2 and Human-Derived Antibody: A Free Energy of Perturbation Retrospective Study. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 6079-6084.	5.4	74
505	SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12114.	4.1	22
506	Immune response against SARS-CoV-2 variants: the role of neutralization assays. <i>Npj Vaccines</i> , 2021, 6, 142.	6.0	26
507	The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. <i>Viruses</i> , 2021, 13, 2391.	3.3	11
509	Fighting SARS-CoV-2 with green seaweed <i>Ulva</i> sp. extract: extraction protocol predetermines crude ulvan extract anti-SARS-CoV-2 inhibition properties in <i>in vitro</i> Vero-E6 cells assay. <i>PeerJ</i> , 2021, 9, e12398.	2.0	8
510	XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants. <i>Frontiers in Immunology</i> , 2021, 12, 761250.	4.8	7

#	ARTICLE	IF	CITATIONS
511	Improved SARS-CoV-2 Spike Glycoproteins for Pseudotyping Lentiviral Vectors. <i>Frontiers in Virology</i> , 2021, 1, .	1.4	1
512	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naïve UK health-care workers: a multicentre prospective cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e21-e31.	7.3	131
513	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	5.6	72
514	Debulking SARS-CoV-2 in saliva using angiotensin converting enzyme 2 in chewing gum to decrease oral virus transmission and infection. <i>Molecular Therapy</i> , 2022, 30, 1966-1978.	8.2	39
515	Nanoparticulate CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice. <i>International Journal of Biological Macromolecules</i> , 2021, 193, 1885-1897.	7.5	12
516	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. <i>Microbiology Spectrum</i> , 2021, 9, e0109621.	3.0	39
518	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- α inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	4.4	31
519	CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern. <i>Microbiology Spectrum</i> , 2021, 9, e0101721.	3.0	40
520	COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine. <i>JAMA Network Open</i> , 2021, 4, e2135044.	5.9	18
521	Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021. <i>Infection, Genetics and Evolution</i> , 2022, 97, 105164.	2.3	9
522	SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021. <i>BMC Medicine</i> , 2021, 19, 303.	5.5	45
523	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. <i>Cell</i> , 2021, 184, 6229-6242.e18.	28.9	72
524	Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2. <i>MBio</i> , 2021, 12, e0231521.	4.1	6
525	SNP and Phylogenetic Characterization of Low Viral Load SARS-CoV-2 Specimens by Target Enrichment. <i>Frontiers in Virology</i> , 2021, 1, .	1.4	6
526	Regulatory challenges of convalescent plasma collection during the evolving stages of COVID-19 pandemic in the United States. <i>Transfusion</i> , 2022, 62, 483-492.	1.6	2
527	Genomic evidence of SARS-CoV-2 reinfection in the Republic of Korea. <i>Journal of Medical Virology</i> , 2022, 94, 1717-1722.	5.0	2
528	Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review. <i>BMJ Open</i> , 2021, 11, e055781.	1.9	22
529	SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera. <i>IScience</i> , 2021, 24, 103467.	4.1	26

#	ARTICLE	IF	CITATIONS
530	Rapid test to assess the escape of SARS-CoV-2 variants of concern. <i>Science Advances</i> , 2021, 7, eabl7682.	10.3	21
531	Validation of a Saliva-Based Test for the Molecular Diagnosis of SARS-CoV-2 Infection. <i>Disease Markers</i> , 2022, 2022, 1-8.	1.3	10
532	Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters. <i>Frontiers in Immunology</i> , 2021, 12, 788235.	4.8	11
533	Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112527.	5.6	34
534	A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients. <i>Gene</i> , 2022, 813, 146113.	2.2	8
535	Transmission cluster of COVID-19 cases from Uruguay: emergence and spreading of a novel SARS-CoV-2 ORF6 deletion. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2022, 116, e210275.	1.6	5
536	Predictive Profiling of SARS-CoV-2 Variants by Deep Mutational Learning. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
538	Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain. <i>Cell Reports Medicine</i> , 2022, 3, 100527.	6.5	47
539	Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 816220.	4.8	22
540	Computational construction of a glycoprotein multi-epitope subunit vaccine candidate for old and new South-African SARS-CoV-2 virus strains. <i>Informatics in Medicine Unlocked</i> , 2022, 28, 100845.	3.4	8
541	A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. <i>Nature Communications</i> , 2022, 13, 155.	12.8	49
543	Structure-guided design of multi-epitopes vaccine against variants of concern (VOCs) of SARS-CoV-2 and validation through In silico cloning and immune simulations. <i>Computers in Biology and Medicine</i> , 2022, 140, 105122.	7.0	4
544	Innovative vaccine approachesâ€”a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2022, 1511, 59-86.	3.8	5
545	DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model. <i>Frontiers in Immunology</i> , 2021, 12, 785349.	4.8	7
546	SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. <i>Cell Reports Medicine</i> , 2022, 3, 100510.	6.5	51
547	The Emergence of the Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic?. <i>Journal of Epidemiology and Global Health</i> , 2022, 12, 143-146.	2.9	27
548	Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. <i>Journal of Clinical Virology</i> , 2022, 146, 105060.	3.1	14
549	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. <i>Immunity</i> , 2022, 55, 355-365.e4.	14.3	76

#	ARTICLE	IF	CITATIONS
550	Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model. <i>Vaccine</i> , 2022, 40, 1289-1298.	3.8	9
551	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	16.0	9
552	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. <i>Cell</i> , 2022, 185, 872-880.e3.	28.9	165
553	The ins and outs of SARS-CoV-2 variants of concern (VOCs). <i>Archives of Virology</i> , 2022, 167, 327-344.	2.1	35
554	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	4.8	176
555	From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. <i>Nano-Micro Letters</i> , 2022, 14, 41.	27.0	26
557	Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks. <i>International Journal of Surgery</i> , 2022, 97, 106204.	2.7	17
560	ExÂvivo and inÂvivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors. <i>Molecular Therapy</i> , 2022, 30, 2005-2023.	8.2	10
561	Genomic surveillance of SARS-CoV-2 Spike gene by sanger sequencing. <i>PLoS ONE</i> , 2022, 17, e0262170.	2.5	15
562	Prolonged Shedding of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at High Viral Loads Among Hospitalized Immunocompromised Persons Living With Human Immunodeficiency Virus (HIV), South Africa. <i>Clinical Infectious Diseases</i> , 2022, 75, e144-e156.	5.8	32
563	Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 72.	4.4	13
564	Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106499.	2.5	15
565	Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India. <i>Journal of Infection and Public Health</i> , 2022, 15, 42-50.	4.1	3
566	Genomic characterization of the dominating Beta, V2Âvariant carrying vaccinated (OxfordâAstraZeneca) and nonvaccinated COVIDâ19 patient samples in Bangladesh: A metagenomics and wholeâgenome approach. <i>Journal of Medical Virology</i> , 2022, 94, 1670-1688.	5.0	6
568	Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China. <i>BMC Medicine</i> , 2022, 20, 37.	5.5	10
569	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	2.6	15
570	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	2.6	22
571	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	3.9	154

#	ARTICLE	IF	CITATIONS
572	USP10 regulates B cell response to SARS-CoV-2 or HIV-1 nanoparticle vaccines through deubiquitinating AID. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 7.	17.1	9
573	Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro. <i>Frontiers in Pharmacology</i> , 2021, 12, 755600.	3.5	34
574	Are convalescent plasma stocks collected during former COVID-19 waves still effective against current SARS-CoV-2 variants?. <i>Vox Sanguinis</i> , 2022, 117, 641-646.	1.5	8
575	R346K Mutation in the μ Variant of SARS-CoV-2 Alters the Interactions with Monoclonal Antibodies from Class 2: A Free Energy Perturbation Study. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 627-631.	5.4	25
576	Predicting spike protein NTD mutations of SARS-CoV-2 causing immune evasion by molecular dynamics simulations. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 3410-3419.	2.8	2
577	SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. <i>Cell Host and Microbe</i> , 2022, 30, 154-162.e5.	11.0	153
578	Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12179.	12.2	24
579	Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus. <i>Frontiers in Medicine</i> , 2021, 8, 793437.	2.6	4
580	Regional and temporal coordinated mutation patterns in SARS-CoV-2 spike protein revealed by a clustering and network analysis. <i>Scientific Reports</i> , 2022, 12, 1128.	3.3	28
581	In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 2649-2655.	3.0	1
582	Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France. <i>Archives of Virology</i> , 2022, 167, 583.	2.1	3
583	Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. <i>IScience</i> , 2022, 25, 103659.	4.1	16
584	Insight into COVID-19's epidemiology, pathology, and treatment. <i>Heliyon</i> , 2022, 8, e08799.	3.2	19
585	Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. <i>Viruses</i> , 2022, 14, 230.	3.3	1
586	Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur. <i>Jurnal Kedokteran Meditek</i> , 2022, 28, 107-119.	0.0	0
587	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 490-495.	30.7	577
588	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	55
589	CoVax501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity. <i>Cell Discovery</i> , 2022, 8, 9.	6.7	12

#	ARTICLE	IF	CITATIONS
590	Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article. International Journal of Surgery, 2022, 98, 106233.	2.7	21
591	Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomal Bovine-Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019. Journal of Infectious Diseases, 2022, 226, 655-663.	4.0	4
592	SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations. Infection and Drug Resistance, 2022, Volume 15, 373-385.	2.7	24
593	Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity. Journal of Infection and Public Health, 2022, 15, 277-288.	4.1	21
594	Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome. Journal of Clinical Investigation, 2022, 132, .	8.2	15
595	Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2. Molecular Therapy, 2022, 30, 1926-1940.	8.2	16
596	Coinfection with SARS-CoV-2 and Influenza A Virus Increases Disease Severity and Impairs Neutralizing Antibody and CD4 ⁺ T Cell Responses. Journal of Virology, 2022, 96, jvi0187321.	3.4	38
597	The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. Journal of Infection and Public Health, 2022, 15, 228-240.	4.1	122
598	Recurrent COVID-19 Polymerase Chain Reaction (PCR) Positivity in 2 Patients During the Current Health Care System Crisis. American Journal of Case Reports, 2022, 23, e935414.	0.8	1
599	501Y.V2 spike protein resists the neutralizing antibody in atomistic simulations. Computational Biology and Chemistry, 2022, 97, 107636.	2.3	1
600	Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. Nature Communications, 2022, 13, 688.	12.8	23
602	Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nature Microbiology, 2022, 7, 423-433.	13.3	78
603	Introduction of the SARS-CoV-2 Beta variant from Comoros into the Marseille geographical area. Travel Medicine and Infectious Disease, 2022, 46, 102277.	3.0	3
604	Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults. Lancet Microbe, The, 2022, 3, e173-e183.	7.3	31
605	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Science Translational Medicine, 2022, 14, eabi9215.	12.4	123
606	The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic. Frontiers in Microbiology, 2022, 13, 789882.	3.5	20
607	Rapid detection of multiple SARS-CoV-2 variants of concern by PAM-targeting mutations. Cell Reports Methods, 2022, 2, 100173.	2.9	12
608	Ad26.COVS.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern. Cell Reports Medicine, 2022, 3, 100535.	6.5	31

#	ARTICLE	IF	CITATIONS
609	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	77
610	Are There Hidden Genes in DNA/RNA Vaccines?. <i>Frontiers in Immunology</i> , 2022, 13, 801915.	4.8	9
613	Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. <i>Annals of Medicine</i> , 2022, 54, 516-523.	3.8	290
614	Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa. <i>IScience</i> , 2022, 25, 103880.	4.1	6
615	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. <i>PLoS Pathogens</i> , 2022, 18, e1010248.	4.7	48
616	Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. <i>Current Microbiology</i> , 2022, 79, 20.	2.2	48
617	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. <i>Cell Reports</i> , 2021, 37, 110143.	6.4	94
618	Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. <i>Cell Reports</i> , 2021, 37, 110156.	6.4	67
619	Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex. <i>EBioMedicine</i> , 2021, 74, 103748.	6.1	17
620	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 0, , .	27.8	104
621	The emergence, genomic diversity and global spread of SARS-CoV-2. <i>Nature</i> , 2021, 600, 408-418.	27.8	249
622	Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta. <i>Nature</i> , 2022, 602, 307-313.	27.8	79
623	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 2022, 602, 654-656.	27.8	928
624	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)â€“Specific Memory B Cells From Individuals With Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern. <i>Journal of Infectious Diseases</i> , 2022, 225, 947-956.	4.0	13
629	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. <i>Science</i> , 2021, 374, 1621-1626.	12.6	232
631	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. <i>ELife</i> , 2021, 10, .	6.0	36
632	Why are some coronavirus variants more infectious?. <i>Journal of Biosciences</i> , 2021, 46, .	1.1	2
633	Vaccine efficacy in mutant SARS-CoV-2 variants. , 2021, 4, 1-12.		4

#	ARTICLE	IF	CITATIONS
634	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2021, , eabm3302.	12.4	13
635	Evolutionary history of the SARS-CoV-2 Gamma variant of concern (P.1): a perfect storm. <i>Genetics and Molecular Biology</i> , 2022, 45, e20210309.	1.3	8
636	Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination. <i>Theranostics</i> , 2022, 12, 2519-2534.	10.0	3
637	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. <i>Pathogens</i> , 2022, 11, 275.	2.8	9
638	COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity. <i>Journal of Microbiology</i> , 2022, 60, 321-334.	2.8	12
640	Assessment of Mutations Associated With Genomic Variants of SARS-CoV-2: RT-qPCR as a Rapid and Affordable Tool to Monitoring Known Circulating Variants in Chile, 2021. <i>Frontiers in Medicine</i> , 2022, 9, 841073.	2.6	2
641	Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation. <i>Frontiers in Immunology</i> , 2022, 13, 840707.	4.8	11
642	Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. <i>Communications Biology</i> , 2022, 5, 169.	4.4	118
643	Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). <i>Scientific Reports</i> , 2022, 12, 2552.	3.3	23
644	Real-Time RT-PCR Allelic Discrimination Assay for Detection of N501Y Mutation in the Spike Protein of SARS-CoV-2 Associated with B.1.1.7 Variant of Concern. <i>Microbiology Spectrum</i> , 2022, 10, e0068121.	3.0	5
646	Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. <i>PLoS Pathogens</i> , 2022, 18, e1010260.	4.7	81
647	Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes. <i>Medical Review</i> , 2022, 2, 3-22.	1.2	7
648	Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City. <i>Viruses</i> , 2022, 14, 545.	3.3	23
649	Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies. <i>Science Advances</i> , 2022, 8, eabm0220.	10.3	18
650	A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant. <i>Vaccines</i> , 2022, 10, 508.	4.4	5
651	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	4.8	9
652	Identifying SARS-CoV-2 Lineage Mutation Hallmarks and Correlating Them With Clinical Outcomes in Egypt: A Pilot Study. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 817735.	3.5	1
653	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. <i>Cell Reports</i> , 2022, 38, 110561.	6.4	16

#	ARTICLE	IF	CITATIONS
654	Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. <i>Nature Communications</i> , 2022, 13, 1699.	12.8	34
655	VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern. <i>Vaccines</i> , 2022, 10, 435.	4.4	8
658	Immunogenicity of the Xcl1-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19. <i>Vaccines</i> , 2022, 10, 407.	4.4	5
659	SARS-CoV-2 mRNA vaccine induced higher antibody affinity and IgG titers against variants of concern in post-partum vs non-post-partum women. <i>EBioMedicine</i> , 2022, 77, 103940.	6.1	3
662	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	4.1	117
663	Structural basis of nanobodies neutralizing SARS-CoV-2 variants. <i>Structure</i> , 2022, 30, 707-720.e5.	3.3	11
664	Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 813-820.	9.1	64
665	AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2. <i>BMC Medicine</i> , 2022, 20, 128.	5.5	17
666	Antigen-antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 797132.	3.5	3
667	Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. <i>Science</i> , 2022, 376, eabn4947.	12.6	651
668	Protective Immunity of the Primary SARS-CoV-2 Infection Reduces Disease Severity Post Re-Infection with Delta Variants in Syrian Hamsters. <i>Viruses</i> , 2022, 14, 596.	3.3	6
669	Inhibition of Respiratory RNA Viruses by a Composition of Ionophoric Polyphenols with Metal Ions. <i>Pharmaceuticals</i> , 2022, 15, 377.	3.8	7
670	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. <i>Science</i> , 2022, 376, eabn8897.	12.6	119
671	Analysis of accumulated SARS-CoV-2 seroconversion in North Carolina: The COVID-19 Community Research Partnership. <i>PLoS ONE</i> , 2022, 17, e0260574.	2.5	3
672	SARS-CoV-2 spike E156G/I ¹⁵⁷⁻¹⁵⁸ mutations contribute to increased infectivity and immune escape. <i>Life Science Alliance</i> , 2022, 5, e202201415.	2.8	24
673	Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation. <i>Stem Cell Research and Therapy</i> , 2022, 13, 126.	5.5	15
674	COVID-19 Outbreaks in Nursing Homes Despite Full Vaccination with BNT162b2 of a Majority of Residents. <i>Gerontology</i> , 2022, 68, 1384-1392.	2.8	9
675	Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. <i>Journal of Microbiology</i> , 2022, 60, 255-267.	2.8	9

#	ARTICLE	IF	CITATIONS
676	A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	49
677	Injectable Slow-Release Hydrogel Formulation of a Plant Virus-Based COVID-19 Vaccine Candidate. <i>Biomacromolecules</i> , 2022, 23, 1812-1825.	5.4	20
678	SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. <i>Cell Host and Microbe</i> , 2022, 30, 880-886.e4.	11.0	80
679	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902.	6.1	23
680	Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 After the Second Wave in South Africa in Human Immunodeficiency Virusâ€“Infected and Uninfected Persons: A Cross-Sectional Household Survey. <i>Clinical Infectious Diseases</i> , 2022, 75, e57-e68.	5.8	11
681	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 951-972.	4.3	4
682	Structural conservation among variants of the SARS-CoV-2 spike postfusion bundle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2119467119.	7.1	25
683	COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants. <i>Bulletin of the National Research Centre</i> , 2022, 46, 96.	1.8	25
686	Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, 1788.	12.8	30
687	Spike protein of SARS-CoV-2 variants: a brief review and practical implications. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1133-1157.	2.0	22
688	Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 1981-1997.	3.8	5
689	Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. <i>Vaccine</i> , 2022, 40, 2960-2969.	3.8	5
690	Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. <i>Nature Communications</i> , 2022, 13, 1976.	12.8	27
691	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104043.	4.1	19
692	Dynamic Ca ²⁺ sensitivity stimulates the evolved SARS-CoV-2 spike strain-mediated membrane fusion for enhanced entry. <i>Cell Reports</i> , 2022, 39, 110694.	6.4	19
693	Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro. <i>Chinese Medicine</i> , 2022, 17, 40.	4.0	8
694	Fast detection of SARS-CoV-2 variants including Omicron using one-step RT-PCR and Sanger sequencing. <i>Journal of Virological Methods</i> , 2022, 304, 114512.	2.1	18
695	Neutralizing Antibodies and Cytokines in Breast Milk After Coronavirus Disease 2019 (COVID-19) mRNA Vaccination. <i>Obstetrics and Gynecology</i> , 2022, 139, 181-191.	2.4	44

#	ARTICLE	IF	CITATIONS
696	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. <i>Frontiers in Pharmacology</i> , 2021, 12, 778219.	3.5	0
701	Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2021, 9, e0165921.	3.0	2
702	Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa. <i>Transactions of the Royal Society of South Africa</i> , 0, , 1-4.	1.1	2
703	A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2021, 12, 765211.	4.8	16
704	Propagation of SARS-CoV-2 in Calu-3 Cells to Eliminate Mutations in the Furin Cleavage Site of Spike. <i>Viruses</i> , 2021, 13, 2434.	3.3	19
705	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	1.7	27
707	An update on host immunity correlates and prospects of re-infection in COVID-19. <i>International Reviews of Immunology</i> , 2022, 41, 367-392.	3.3	9
708	Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13202.	4.1	20
709	Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 795741.	4.8	13
710	Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2022, 75, e857-e864.	5.8	30
711	Estimating the strength of selection for new SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 7239.	12.8	23
712	Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres. <i>Transfusion Medicine</i> , 2022, 32, 327-337.	1.1	5
713	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. <i>Cell Reports</i> , 2022, 39, 110757.	6.4	10
714	DeepSARS: simultaneous diagnostic detection and genomic surveillance of SARS-CoV-2. <i>BMC Genomics</i> , 2022, 23, 289.	2.8	5
716	Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city. <i>Communications Medicine</i> , 2022, 2, .	4.2	32
717	Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	8.3	16
718	Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. , 2022, 13, 402.		28
719	SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in the COVID-19 Pandemic in Palembang Indonesia.. <i>Acta Biomedica</i> , 2022, 93, e2022018.	0.3	0

#	ARTICLE	IF	CITATIONS
720	Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity.. Science Translational Medicine, 2021, , eabj6824.	12.4	11
721	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
722	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs, 2022, 36, 231-323.	4.6	24
723	Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19. Frontiers in Drug Discovery, 2022, 2, .	2.8	5
724	SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance. Frontiers in Immunology, 2022, 13, 877101.	4.8	74
725	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell, 2022, 185, 2265-2278.e14.	28.9	77
726	Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. Human Vaccines and Immunotherapeutics, 2022, 18, 2068883.	3.3	44
727	Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota. Communications Biology, 2022, 5, 439.	4.4	9
728	Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection. Biochemistry, 2022, 61, 963-980.	2.5	12
729	Whole genome sequencing of SARS-CoV2 strains circulating in Iran during five waves of pandemic. PLoS ONE, 2022, 17, e0267847.	2.5	20
730	Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing. Molecular Diversity, 2023, 27, 463-475.	3.9	25
731	Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host. Nature Communications, 2022, 13, 2560.	12.8	64
732	Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 – A Comprehensive Analysis. Frontiers in Immunology, 2022, 13, 841009.	4.8	0
733	Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. Molecular Therapy, 2022, 30, 2952-2967.	8.2	2
734	Human-to-dog transmission of SARS-CoV-2, Colombia. Scientific Reports, 2022, 12, 7880.	3.3	9
735	Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern. Virology, 2022, 572, 44-54.	2.4	21
736	Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational impacts, concerns, and the possible solutions. Annals of Medicine and Surgery, 2022, 78, 103737.	1.1	33
737	Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. EBioMedicine, 2022, 80, 104062.	6.1	10

#	ARTICLE	IF	CITATIONS
738	Safety & effectiveness of COVID-19 vaccines: A narrative review. Indian Journal of Medical Research, 2022, 155, 91.	1.0	22
740	Modeling Infectious Behaviors: The Need to Account for Behavioral Adaptation in COVID-19 Models.. Journal on Policy and Complex Systems, 2021, 7, 21-32.	0.1	0
743	Role of COVID-19 Vaccines in SARS-CoV-2 Variants. Frontiers in Immunology, 2022, 13, .	4.8	37
744	The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. Frontiers in Medicine, 2022, 9, .	2.6	43
745	Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England. Epidemiology and Infection, 2022, 150, .	2.1	8
746	Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein. Cell, 2022, 185, 2279-2291.e17.	28.9	25
747	VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages. Journal of Personalized Medicine, 2022, 12, 895.	2.5	2
748	A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus. Applied Microbiology and Biotechnology, 2022, 106, 4091-4114.	3.6	6
749	Leveraging on past investment in understanding the immunology of COVID-19 “ the South African experience. South African Journal of Science, 2022, 118, .	0.7	1
750	Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor. Journal of Cellular Biochemistry, 2022, 123, 1207-1221.	2.6	3
751	Leveraging South African <sc>HIV</sc> research to define <sc>SARS-CoV</sc> immunity triggered by sequential variants of concern. Immunological Reviews, 2022, 310, 61-75.	6.0	6
752	Prognosis of patients with acute respiratory failure due to the SARS-CoV-2 501Y.V2 variant: a multicenter retrospective matched cohort study. Scientific Reports, 2022, 12, .	3.3	2
753	An early warning system for emerging SARS-CoV-2 variants. Nature Medicine, 2022, 28, 1110-1115.	30.7	47
754	Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 0, 9, .	2.6	25
755	A random priming amplification method for whole genome sequencing of SARS-CoV-2 virus. BMC Genomics, 2022, 23, .	2.8	6
756	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis. Lancet Microbe, The, 2022, 3, e493-e502.	7.3	22
757	SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. Small, 2022, 18, .	10.0	11
758	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nature Immunology, 2022, 23, 960-970.	14.5	39

#	ARTICLE	IF	CITATIONS
759	Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection. <i>Emerging Microbes and Infections</i> , 2022, 11, 1500-1507.	6.5	1
760	An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques. , 2022, 1, .		10
761	Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants. <i>Viruses</i> , 2022, 14, 1332.	3.3	12
762	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	4.4	23
763	Synergistic interactions of repurposed drugs that inhibit Nsp1, a major virulence factor for COVID-19. <i>Scientific Reports</i> , 2022, 12, .	3.3	9
764	Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion Article. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	0
765	Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6830.	4.1	5
766	Potent human broadly SARS-CoV-2â€œneutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	34
768	Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2. <i>Transfusion Medicine Reviews</i> , 2022, 36, 125-132.	2.0	8
769	An updated review of <scp>SARSâ€œCoV</scp>â€œ2 detection methods in the context of a novel coronavirus pandemic. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	7.1	19
771	Automated Library Construction and Analysis for High-throughput Nanopore Sequencing of SARS-CoV-2. <i>journal of applied laboratory medicine</i> , The, 0, , .	1.3	0
772	Microbiome Analysis for Wastewater Surveillance during COVID-19. <i>MBio</i> , 2022, 13, .	4.1	40
773	Structural basis of Omicron immune evasion: A comparative computational study. <i>Computers in Biology and Medicine</i> , 2022, 147, 105758.	7.0	6
775	Inhibitors of Deubiquitinating Enzymes Interfere with the SARS-CoV-2 Papain-like Protease and Block Virus Replication In Vitro. <i>Viruses</i> , 2022, 14, 1404.	3.3	7
776	The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. <i>PLoS Pathogens</i> , 2022, 18, e1010592.	4.7	13
777	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	28
778	Will Peptides Help to Stop COVID-19?. <i>Biochemistry (Moscow)</i> , 2022, 87, 590-604.	1.5	1
781	Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7675.	4.1	9

#	ARTICLE	IF	CITATIONS
782	A review of mass spectrometry-based analyses to understand COVID-19 convalescent plasma mechanisms of action. <i>Proteomics</i> , 0, , 2200118.	2.2	3
783	Two Years of Evolutionary Dynamics of SARS-CoV-2 in Mexico, With Emphasis on the Variants of Concern. <i>Frontiers in Microbiology</i> , 0, 13, .	3.5	3
784	Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 5707-5727.	3.5	7
785	COVID-19: Challenges of Viral Variants. <i>Annual Review of Medicine</i> , 2023, 74, 31-53.	12.2	43
786	Early detection and surveillance of SARS-CoV-2 genomic variants in wastewater using COJAC. <i>Nature Microbiology</i> , 2022, 7, 1151-1160.	13.3	69
787	What, Where, When and How of COVID-19 Patents Landscape: A Bibliometrics Review. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	2
788	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	6
789	Host-Genome Similarity Characterizes the Adaption of SARS-CoV-2 to Humans. <i>Biomolecules</i> , 2022, 12, 972.	4.0	1
790	Novel Lateral Flow-Based Assay for Simple and Visual Detection of SARS-CoV-2 Mutations. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	3.9	1
791	Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. <i>Journal of Virology</i> , 2022, 96, .	3.4	7
792	Comparison of viral propagation and drug response among SARS-CoV-2 VOCs using replicons capable of recapitulating virion assembly and release. <i>Virologica Sinica</i> , 2022, 37, 695-703.	3.0	1
794	Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition. <i>ELife</i> , 0, 11, .	6.0	12
795	Interferon resistance of emerging SARS-CoV-2 variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	63
796	Potent and Broad Neutralization of SARS-CoV-2 Variants of Concern (VOCs) including Omicron Sub-lineages BA.1 and BA.2 by Biparatopic Human VH Domains. <i>IScience</i> , 2022, , 104798.	4.1	1
798	Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. <i>International Journal of Biological Sciences</i> , 2022, 18, 4629-4641.	6.4	24
799	Perspective Chapter: Bioinformatics Study of the Evolution of SARS-CoV-2 Spike Protein. <i>Infectious Diseases</i> , 0, , .	4.0	0
800	SARS-CoV-2 S2a-targeted vaccination elicits broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	57
801	Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3

#	ARTICLE	IF	CITATIONS
802	Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics. <i>Viruses</i> , 2022, 14, 1603.	3.3	27
804	Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From Adult Index Cases With and Without Human Immunodeficiency Virus in South Africa, 2020â€“2021: A Case-Ascertained, Prospective, Observational Household Transmission Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e71-e81.	5.8	6
805	Virtual screening reveals liquiritigenin as a broad-spectrum inhibitor of SARS-CoV-2 variants of concern: an <i>in silico</i> study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 6709-6727.	3.5	2
806	COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy. <i>Translational Research</i> , 2023, 251, 84-95.	5.0	14
807	Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways. <i>IScience</i> , 2022, 25, 104914.	4.1	5
808	SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition. <i>Viruses</i> , 2022, 14, 1861.	3.3	4
809	A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. <i>Journal of Virology</i> , 2022, 96, .	3.4	14
810	Association Between Human Immunodeficiency Virus Viremia and Compromised Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant. <i>Journal of Infectious Diseases</i> , 2023, 227, 211-220.	4.0	6
811	Homologous or Heterologous COVID-19 Booster Regimens Significantly Impact Sero-Neutralization of SARS-CoV-2 Virus and Its Variants. <i>Vaccines</i> , 2022, 10, 1321.	4.4	4
812	Characterization of a broadly cross reactive tetravalent human monoclonal antibody, recognizing conformational epitopes in receptor binding domain of SARS-CoV-2. <i>3 Biotech</i> , 2022, 12, .	2.2	2
813	Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-13.	1.9	5
814	Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
815	Molecular Dynamics Analysis of Fast-Spreading Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Their Effects on the Interaction with Human Angiotensin-Converting Enzyme 2. <i>ACS Omega</i> , 2022, 7, 30700-30709.	3.5	6
816	Epitopes mapped onto SARS-CoV-2 receptor-binding motif by five distinct human neutralising antibodies. <i>Molecular Simulation</i> , 0, , 1-11.	2.0	0
817	Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents. <i>Communications Biology</i> , 2022, 5, .	4.4	11
818	Design and Immunoinformatic Assessment of Candidate Multivariant mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2. <i>Polymers</i> , 2022, 14, 3263.	4.5	3
819	Efficacy and safety of COVIDâ€™19 vaccines: A network metaâ€analysis. <i>Journal of Evidence-Based Medicine</i> , 2022, 15, 245-262.	1.8	14
820	Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). <i>Journal of Intensive Medicine</i> , 2022, 2, 199-222.	2.1	3

#	ARTICLE	IF	CITATIONS
821	Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants. Journal of Clinical Immunology, 2023, 43, 31-45.	3.8	4
823	Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019â€“2022. PLoS ONE, 2022, 17, e0271074.	2.5	14
824	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. Science Translational Medicine, 2022, 14, .	12.4	15
825	Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2. Frontiers in Immunology, 0, 13, .	4.8	3
826	Temporal lineage replacements and dominance of imported variants of concern during the COVID-19 pandemic in Kenya. Communications Medicine, 2022, 2, .	4.2	4
827	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. International Immunopharmacology, 2022, 111, 109128.	3.8	9
828	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. Biomedicine and Pharmacotherapy, 2022, 154, 113522.	5.6	56
829	From Alpha to Omicron BA.2: New digital RT-PCR approach and challenges for SARS-CoV-2 VOC monitoring and normalization of variant dynamics in wastewater. Science of the Total Environment, 2022, 848, 157740.	8.0	13
830	State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic. OpenNano, 2022, 8, 100078.	4.8	11
831	Learnings from the Australian first few X household transmission project for COVID-19. The Lancet Regional Health - Western Pacific, 2022, 28, 100573.	2.9	3
832	Mathematical artificial intelligence design of mutation-proof COVID-19 monoclonal antibodies. Communications in Information and Systems, 2022, 22, 339-361.	0.5	2
833	SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. , 2022, , 143-160.		0
834	Genetics and Biological Characteristics of SARS-CoV-2. , 2022, , 49-66.		0
835	Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial. SSRN Electronic Journal, 0, , .	0.4	0
836	Antibody-mediated immunity to SARS-CoV-2 spike. Advances in Immunology, 2022, , 1-69.	2.2	12
837	SARSâ€“CoVâ€“2 does not infect pigs, but this has to be verified regularly. Xenotransplantation, 2022, 29, .	2.8	3
838	Potential Therapeutic Role of Mesenchymal-Derived Stem Cells as an Alternative Therapy to Combat COVID-19 through Cytokines Storm. Cells, 2022, 11, 2686.	4.1	1
839	Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spikeâ€“ACE2 Proteinâ€“Protein Interaction from a Chemical Space of Privileged Protein Binders. Pharmaceuticals, 2022, 15, 1084.	3.8	5

#	ARTICLE	IF	CITATIONS
840	Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. <i>Cell</i> , 2022, 185, 4008-4022.e14.	28.9	55
841	A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
842	Mutations in SARS-CoV-2 nucleocapsid in variants of concern impair the sensitivity of SARS-CoV-2 detection by rapid antigen tests. <i>Frontiers in Virology</i> , 0, 2, .	1.4	3
844	Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 41, 111528.	6.4	6
845	Dynamics of Neutralizing Antibodies and Binding Antibodies to Domains of SARS-CoV-2 Spike Protein in COVID-19 Survivors. <i>Viral Immunology</i> , 2022, 35, 545-552.	1.3	4
847	Perspective Chapter: Real-Time Genomic Surveillance for SARS-CoV-2 on Center Stage. <i>Infectious Diseases</i> , 0, , .	4.0	0
848	A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 1655.	4.4	12
849	Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1bâ€“2a trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 295-306.	9.1	14
850	SARS-CoV-2 variants of concern: a review. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.6	4
851	Etiology and Epidemiology of Croup before and throughout the COVID-19 Pandemic, 2018â€“2022, South Korea. <i>Children</i> , 2022, 9, 1542.	1.5	2
852	HIV skews the SARS-CoV-2 B cell response towards an extrafollicular maturation pathway. <i>ELife</i> , 0, 11, .	6.0	6
853	Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history. <i>Cell Host and Microbe</i> , 2022, 30, 1745-1758.e7.	11.0	31
854	Proteins from Thermophilic <i>Thermus thermophilus</i> Often Do Not Fold Correctly in a Mesophilic Expression System Such as <i>Escherichia coli</i> . <i>ACS Omega</i> , 2022, 7, 37797-37806.	3.5	2
856	Versatile live-attenuated SARS-CoV-2 vaccine platform applicable to variants induces protective immunity. <i>IScience</i> , 2022, 25, 105412.	4.1	8
857	Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 113977.	5.6	66
858	<i>In silico</i> study identifies peptide inhibitors that negate the effect of non-synonymous mutations in major drug targets of SARS-CoV-2 variants. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 9551-9561.	3.5	1
859	Reporting complete heart block in a patient with polyarteritis nodosa after COVIDâ€“19 vaccination. <i>ESC Heart Failure</i> , 2023, 10, 1418-1421.	3.1	6
860	A potent, broadly protective vaccine against SARS-CoV-2 variants of concern. <i>Npj Vaccines</i> , 2022, 7, .	6.0	8

#	ARTICLE	IF	CITATIONS
861	Genome characterization, phylogenomic assessment and spatio-temporal dynamics study of highly mutated BA variants from India. Indian Journal of Medical Microbiology, 2022, , .	0.8	1
862	Mutation and SARS-CoV-2 strain competition under vaccination in a modified SIR model. Chaos, Solitons and Fractals, 2023, 166, 112964.	5.1	4
863	A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling. Journal of Biomedical Research, 2023, 37, 166.	1.6	1
864	Coronavirus disease 2019: current understanding of its pathophysiology and histopathological findings. Journal of the Arab Society for Medical Research, 2022, 17, 108.	0.0	0
865	SARS-CoV-2 Omicron Variant Genomic Sequences and Their Epidemiological Correlates Regarding the End of the Pandemic: In Silico Analysis. JMIR Bioinformatics and Biotechnology, 0, 4, e42700.	0.9	2
866	Modelling optimal lockdowns with waning immunity. Economic Theory, 2024, 77, 197-234.	0.9	7
867	Serological and Molecular Surveillance for SARS-CoV-2 Infection in Captive Tigers (Panthera tigris), Thailand. Animals, 2022, 12, 3350.	2.3	4
868	Saliva and Plasma Neutralizing Activity Induced by the Administration of a Third bnt162b2 Vaccine Dose. International Journal of Molecular Sciences, 2022, 23, 14341.	4.1	4
869	As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?. Frontiers in Public Health, 0, 10, .	2.7	5
870	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. Biochemical Society Transactions, 2022, 50, 1643-1658.	3.4	6
871	Challenges and developments in universal vaccine design against SARS-CoV-2 variants. Npj Vaccines, 2022, 7, .	6.0	25
873	Label-Free Analysis of Binding and Inhibition of SARS-Cov-19 Spike Proteins to ACE2 Receptor with ACE2-Derived Peptides by Surface Plasmon Resonance. ACS Applied Bio Materials, 2023, 6, 182-190.	4.6	1
874	Progress Update on the Epidemiology of COVID-19 Variants and the Assessment Status of Developed Vaccines. Journal of Pharmacology and Pharmacotherapeutics, 2022, 13, 293-299.	0.4	0
876	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. Journal of Taibah University Medical Sciences, 2023, 18, 600-638.	0.9	1
877	Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants. Vaccines, 2022, 10, 2110.	4.4	2
878	Evaluation of antibody response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine in a correctional facility. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	3
879	The SARS-CoV-2 Delta (B.1.617.2) variant with Spike N501Y mutation in the shadow of Omicron emergence. Heliyon, 2022, , e12650.	3.2	0
880	Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations. Microorganisms, 2023, 11, 30.	3.6	11

#	ARTICLE	IF	CITATIONS
881	Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant. Scientific Reports, 2022, 12, .	3.3	5
882	Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant. Cell Reports Medicine, 2023, 4, 100910.	6.5	5
883	Simultaneous spectrofluorimetric determination of remdesivir and simeprevir in human plasma. Scientific Reports, 2022, 12, .	3.3	3
884	A bivalent subunit vaccine efficiently produced in Pichia pastoris against SARS-CoV-2 and emerging variants. Frontiers in Microbiology, 0, 13, .	3.5	2
885	Refocus on Immunogenic Characteristics of Convalescent COVID-19 Challenged by Prototype SARS-CoV-2. Vaccines, 2023, 11, 123.	4.4	3
886	European Black Elderberry Fruit Extract Inhibits Replication of SARS-CoV-2 In Vitro. Nutraceuticals, 2023, 3, 91-106.	1.7	3
887	RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers. Microbiology Spectrum, 2023, 11, .	3.0	1
888	A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model. Journal of Virology, 0, , .	3.4	2
889	S Trimer Derived from SARS-CoV-2 B.1.351 and B.1.618 Induced Effective Immune Response against Multiple SARS-CoV-2 Variants. Vaccines, 2023, 11, 193.	4.4	1
890	Functional studies of HLA and its role in SARS-CoV-2: Stimulating T cell response and vaccine development. Life Sciences, 2023, 315, 121374.	4.3	3
891	From Challenges to Opportunities and Open Questions. , 2023, , 87-130.		0
892	Safeguarding Against the Analog of Antimicrobial-Resistance Development. , 2023, , 163-176.		0
893	Scales, Pseudoscales, the Human Factor, and a Way Forward. , 2023, , 177-224.		0
895	Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination—Evidence Synthesis and Implications for New COVID-19 Vaccines. Biomedicines, 2023, 11, 370.	3.2	15
896	Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2. Nature Communications, 2023, 14, .	12.8	8
897	Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy. Viral Immunology, 0, , .	1.3	1
898	Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape. Nature Communications, 2023, 14, .	12.8	21
899	Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19. Viruses, 2023, 15, 448.	3.3	0

#	ARTICLE	IF	CITATIONS
901	Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes. <i>Cell Reports</i> , 2023, 42, 112370.	6.4	2
902	Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
903	COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease. <i>Drug Discovery Today</i> , 2023, 28, 103579.	6.4	22
904	Defending against SARS-CoV-2: The T cell perspective. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	20
905	Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic. <i>Genes</i> , 2023, 14, 407.	2.4	10
906	Evaluation of possible COVID-19 reinfection in children: A multicenter clinical study. <i>Archives De Pediatrie</i> , 2023, 30, 187-191.	1.0	2
907	A case of reinfection with a different variant of SARS-CoV-2: case report. <i>The Egyptian Journal of Internal Medicine</i> , 2023, 35, .	0.9	1
908	SARS-CoV-2 multi-antigen protein microarray for detailed characterization of antibody responses in COVID-19 patients. <i>PLoS ONE</i> , 2023, 18, e0276829.	2.5	4
909	Protein expression/secretion boost by a novel unique 21-mer cis-regulatory motif (Exin21) via mRNA stabilization. <i>Molecular Therapy</i> , 2023, 31, 1136-1158.	8.2	1
910	The impact of COVID-19 and COVID vaccination on cardiovascular outcomes. <i>European Heart Journal Supplements</i> , 2023, 25, A42-A49.	0.1	10
911	Severe Acute Respiratory Syndrome Coronaviruses-2 (SARS-CoV-2). , 2023, , 1-15.		0
912	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. <i>Immunity</i> , 2023, 56, 669-686.e7.	14.3	43
913	Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method. <i>Antibody Therapeutics</i> , 2023, 6, 76-86.	1.9	0
914	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	3.2	28
915	A DNA Vaccine Encoding the Full-Length Spike Protein of Beta Variant (B.1.351) Elicited Broader Cross-Reactive Immune Responses against Other SARS-CoV-2 Variants. <i>Vaccines</i> , 2023, 11, 513.	4.4	5
916	Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2023, 15, 624.	3.3	4
917	Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits. <i>Vaccine</i> , 2023, 41, 2261-2269.	3.8	4
918	Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants. <i>Nature Communications</i> , 2023, 14, .	12.8	8

#	ARTICLE	IF	CITATIONS
919	Variants of SARS-CoV-2: Influences on the Vaccines™ Effectiveness and Possible Strategies to Overcome Their Consequences. Medicina (Lithuania), 2023, 59, 507.	2.0	5
920	The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients. Frontiers in Cellular and Infection Microbiology, 0, 13, .	3.9	3
921	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. Medicinal Research Reviews, 2023, 43, 932-971.	10.5	7
922	Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern. Journal of Medical Virology, 2023, 95, .	5.0	1
923	SARS-CoV-2 M ^{pro} Protease Variants of Concern Display Altered Viral Substrate and Cell Host Target Galectin-8 Processing but Retain Sensitivity toward Antivirals. ACS Central Science, 2023, 9, 696-708.	11.3	14
924	Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review. Cureus, 2023, , .	0.5	1
926	Anti-COVID-19 Credentials of Chitosan Composites and Derivatives: Future Scope?. Antibiotics, 2023, 12, 665.	3.7	1
927	Comprehensive deep mutational scanning reveals the pH induced stability and binding differences between SARS-CoV-2 spike RBD and human ACE2. Journal of Biomolecular Structure and Dynamics, 2023, 41, 15207-15218.	3.5	1
928	HLA Variation and SARS-CoV-2 Specific Antibody Response. Viruses, 2023, 15, 906.	3.3	4
929	Immunology of COVID-19. , 2024, , 52-71.		0
930	The importance of combining serological testing with RT-PCR assays for efficient detection of COVID-19 and higher diagnostic accuracy. PeerJ, 0, 11, e15024.	2.0	4
931	Phytochemicals of Withania somnifera as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. Microorganisms, 2023, 11, 1000.	3.6	2
933	Comparison of the immunogenicity of nasal-spray rVSV vector, adenovirus vector, and inactivated COVID-19-based vaccines in rodent models. Journal of Medical Virology, 2023, 95, .	5.0	1
934	A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8. Nature Communications, 2023, 14, .	12.8	5
935	A SARS-CoV-2: Companion Animal Transmission and Variants Classification. Pathogens, 2023, 12, 775.	2.8	3
936	Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	7.1	9
937	Upgrading nirmatrelvir to inhibit SARS-CoV-2 M ^{pro} via DeepFrag and free energy calculations. Journal of Molecular Graphics and Modelling, 2023, 124, 108535.	2.4	2
938	A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells. Frontiers in Immunology, 0, 14, .	4.8	1

#	ARTICLE	IF	CITATIONS
939	Evolution of Sequence and Structure of SARS-CoV-2 Spike Protein: A Dynamic Perspective. ACS Omega, 0, , .	3.5	1
940	Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination. IScience, 2023, 26, 107208.	4.1	0
941	SARS-CoV-2 Spike N-Terminal Domain Engages 9-O-Acetylated α -8-Linked Sialic Acids. ACS Chemical Biology, 2023, 18, 1180-1191.	3.4	5
942	Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail. Cell Reports, 2023, 42, 112621.	6.4	2
943	Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters. Communications Medicine, 2023, 3, .	4.2	1
944	Development and application of an RT-PCR assay for the identification of the delta and omicron variants of SARS-COV-2. Heliyon, 2023, 9, e16917.	3.2	0
945	Iota-Carrageenan Inhibits Replication of the SARS-CoV-2 Variants of Concern Omicron BA.1, BA.2 and BA.5. Nutraceuticals, 2023, 3, 315-328.	1.7	2
946	Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19. Frontiers in Immunology, 0, 14, .	4.8	1
947	The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2. Frontiers in Microbiology, 0, 14, .	3.5	2
948	Association of close-range contact patterns with SARS-CoV-2: a household transmission study. ELife, 0, 12, .	6.0	1
949	Challenges and opportunities of molecular epidemiology: using omics to address complex One Health issues in tropical settings. Frontiers in Tropical Diseases, 0, 4, .	1.4	1
950	An Extended AHP-Based Corpus Assessment Approach for Handling Keyword Ranking of NLP: An Example of COVID-19 Corpus Data. Axioms, 2023, 12, 740.	1.9	4
951	Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination. Frontiers in Immunology, 0, 14, .	4.8	2
952	From Alpha to Omicron: How Different Variants of Concern of the SARS-Coronavirus-2 Impacted the World. Biology, 2023, 12, 1267.	2.8	7
953	Real-Time Analysis of SARS-CoV-2-Induced Cytolysis Reveals Distinct Variant-Specific Replication Profiles. Viruses, 2023, 15, 1937.	3.3	1
954	Wastewater-based Epidemiology and SARS-CoV-2: Variant Trends in the Apulia Region (Southern Italy) and Effect of Some Environmental Parameters. Food and Environmental Virology, 2023, 15, 331-341.	3.4	1
955	Characteristics of epitope dominance pattern and cross-variant neutralisation in 16 SARS-CoV-2 mRNA vaccine sera. Vaccine, 2023, 41, 6248-6254.	3.8	0
956	Subunit vaccine raised against the SARS-CoV-2 spike of Delta and Omicron variants. Journal of Medical Virology, 2023, 95, .	5.0	1

#	ARTICLE	IF	CITATIONS
957	The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution. <i>Vaccines</i> , 2023, 11, 1472.	4.4	2
958	A Suitable Membrane Distance Regulated by the RBD_ACE2 Interaction is Critical for SARS-CoV-2 Spike-Mediated Viral Invasion. <i>Advanced Science</i> , 2023, 10, .	11.2	0
961	Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine. <i>Vaccine</i> , 2023, 41, 6505-6513.	3.8	1
962	Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants. <i>Drug Resistance Updates</i> , 2023, 71, 101008.	14.4	0
963	A Comprehensive analysis of covid-19: An overview. , 2023, 2, 47.		0
964	Riding the Wave: Unveiling the Conformational Waves from RBD of SARS-CoV-2 Spike Protein to ACE2. <i>Journal of Physical Chemistry B</i> , 2023, 127, 8525-8536.	2.6	0
965	Severe Acute Respiratory Syndrome Coronaviruses-2 (SARS-CoV-2). , 2023, , 1529-1543.		0
966	Humoral and cellular immunity against diverse SARS-CoV-2 variants. <i>Journal of Genetics and Genomics</i> , 2023, 50, 934-947.	3.9	1
967	Dynamics analysis of a stochastic SIRVI epidemic model with weak immunity. <i>Applied Mathematics Letters</i> , 2023, , 108898.	2.7	1
968	Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology. <i>Nature Communications</i> , 2023, 14, .	12.8	0
969	A validated eco-friendly HPLC-FLD for analysis of the first approved antiviral remdesivir with other potential add-on therapies for COVID-19 in human plasma and pharmaceuticals. <i>Analytical Methods</i> , 2023, 15, 6666-6678.	2.7	0
972	To be remembered: B cell memory response against SARS-CoV-2 and its variants in vaccinated and unvaccinated individuals. <i>Scandinavian Journal of Immunology</i> , 0, , .	2.7	0
973	COVID-19: From emerging variants to vaccination. <i>Cytokine and Growth Factor Reviews</i> , 2023, , .	7.2	1
974	Innovation-driven trend shaping COVID-19 vaccine development in China. <i>Frontiers of Medicine</i> , 2023, 17, 1096-1116.	3.4	0
976	Importance of Timely Sequencing, Tracking, and Surveillance of Emergent Variants. , 2024, , 166-193.		0
978	SERUM FERRITIN AND SERUM LACTATE DEHYDROGENASE LEVELS AMONG COVID-19 PATIENTS. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 30-32.	0.3	0
979	RT-PCR genotyping assays to identify SARS-CoV-2 variants in England in 2021: a design and retrospective evaluation study. <i>Lancet Microbe</i> , The, 2024, 5, e173-e180.	7.3	0
980	Therapeutic landscape of SARS-CoV-2. , 2024, , 83-99.		0

#	ARTICLE	IF	CITATIONS
981	Paradigm of immune dysregulation in coronavirus disease-2019 infection. Exploration of Immunology, 0, , 1-33.	0.3	0
982	Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein. Journal of Infection, 2024, 88, 106121.	3.3	0
983	Interferon-stimulated gene PVRL4 broadly suppresses viral entry by inhibiting viral-cellular membrane fusion. Cell and Bioscience, 2024, 14, .	4.8	0
984	Wastewater sequencing as a powerful tool to reveal SARS-CoV-2 variant introduction and spread in French Guiana, South America. Science of the Total Environment, 2024, 924, 171645.	8.0	0